Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-04-05
2011-04-05
Kelly, Robert M (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200, C536S023500
Reexamination Certificate
active
07919478
ABSTRACT:
A method and means have been developed to deliver a therapeutic dose or dosages of the angiogenic molecule, Vascular Endothelial Growth Factor (VEGF) that results in a statically significant decrease in the time to achieve 100% wound closure and accelerates the rate of healing in experimental diabetic ulcers. Toxicity is evaluated by measuring any local inflammatory response at the wound site, the systemic absorption of VEGF, and the effect on distant organs that may be particularly susceptible to VEGF therapy (e.g., retinopathy and hepatitis) The angiogenic response is quantified by measuring the change in collagen deposition, epithelialization, and the closure rates of diabetic ulcers after therapeutic dosing with ADV-VEGF. Sustained administration of VEGF, stimulates and accelerates the healing process as evidenced by a reduced time to complete healing (defined by 100% epithelialization and no drainage) in experimental diabetic ulcers, with minimal to no toxicity. Important features of the method and reagents for use therein are that the VEGF is released into the ulcer in a sufficient quantity over a period of time for at least two to six weeks, or to closure of the wound.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5879713 (1999-03-01), Roth et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6329348 (2001-12-01), Crystal et al.
patent: 6596296 (2003-07-01), Nelson et al.
patent: 6821512 (2004-11-01), Gao et al.
patent: 7223740 (2007-05-01), Visser et al.
patent: WO 00/54745 (2000-09-01), None
Kaya, et al. (2001) Sarcoma, 5(4): 197-202.
Bennett, et al. (2003) British Journal of Surgery, 90: 133-146.
Abraham, et al., “Psoriasis, necrobiosis lipoidica, granuloma annnulare, vitiligo and skin infections in the same diabetic patient,”J. Dermatol.17(7): 440-447 (1990).
Acsadi, et al., “Human dystrophin expression in mdx mice after intramuscular injection of DNA construct,”Nature352(6338): 815-818 (1991).
Albertson, et al., “PDGF and FGF reverse the healing impairment in protein-malnourished diabetic mice,”Surgery114(2): 368-373 (1993).
Altavilla, et al., “Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse,”Diabetes50(3): 667-674 (2001).
Arbiser, “Angiogenesis and the skin: a primer,”J. Am. Acad. Dermatol.34(3): 486-497 (1996).
Arnold & West, “Angiogenesis in wound healing,”Pharmacol. Ther.52(3): 407-422 (1991).
Banai, et al., “Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs,”Circulation89(5): 2183-2189 (1994).
Banks, et al., “Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology,”Br. J. Cancer77(6): 956-964 (1998).
Baumgartner, et al., “Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia,”Circulation97(12): 1114-1123 (1998).
Baumgartner, et al., “Somatic gene therapy in the cardiovascular system,”Annu. Rev. Physiol.63: 427-450 (2001).
Bauters, et al., “Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor,”Circulation91(11): 2802-2809 (1995).
Bauters, et al., “Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor,”J. Vasc. Surg.21(2): 314-325 (1995).
Beer, et al., “Reduced expression of PDGF and PDGF receptors during impaired wound healing,”J. Invest. Dermatol.109(2): 132-138 (1997).
Bennett, “Growth factors in the treatment of diabetic foot ulcers.”British Journal of Surgery90:133-46 (2003).
Berse, et al., “Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors,”Mol. Biol. Cell3(2): 211-220 (1992).
Bessman & Sapico, “Infections in the diabetic patient: the role of immune dysfunction and pathogen virulence factors,”J. Diabetes Complications6(4): 258-262 (1992).
Bett, et al., “Packaging capacity and stability of human adenovirus type 5 vectors,”J. Virol.67(10): 5911-5921 (1993).
Bramson, et al., “Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination,”Gene Ther.4(10): 1069-1076 (1997).
Brem & Folkman, “Angiogenesis and basic firbroblast growth factor during wound healing,” inBone Formation and Repair(Brighton, et al., eds.) American Academy of Orthopaedic Surgeons: Rosemont, Illinois, pp. 213-222 (1994).
Brem, et al., “Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent,”Arch. Surg.135: 627-634 (2000).
Brogi, et al., “Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only,”Circulation90(2): 649-652 (1994).
Brown, et al., “Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and nondiabetic mice,”Am. J. Pathol.151(3): 715-724 (1997).
Brown, et al., “PDGF and TGF-alpha act synergistically to improve wound healing in the genetically diabetic mouse,”J. Surg. Res.56(6): 562-570 (1994).
Coleman, “Diabetes-obesity syndromes in mice,”Diabetes31(Suppl 1; Pt 2): 1-6 (1982).
Connolly, et al., “Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis,”J. Clin. Invest.84(5): 1470-1478 (1989).
Corral, et al., “Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing,”Arch. Surg.134(2): 200-205 (1999).
Darby, et al., “Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice,”Int. J. Biochem. Cell Biol.29: 191-200 (1997).
Esakof, et al., “Intraoperative multiplane transesophageal echocardiography for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris,”Hum. Gene Ther.10(14): 2307-2314 (1999).
Feige & Van Eden, “Infection, autoimmunity and autoimmune disease,”EXS77: 359-373 (1996).
Feng, et al., “Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme,”Cancer Res.55(10): 2024-2028 (1995).
Ferrara & Henzel, “Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells,”Biochem. Biophys. Res. Comm.161(2): 851-858 (1989).
Ferrara, “Molecular and biological properties of vascular endothelial growth factor,”J. Mol. Med.77(7): 527-543 (1999).
Folkman & Brem, “Angiogenesis and inflammation,” inInflammation: Basic Principles and Clinical Correlates, 2nded., (Gallin, et al., eds.) Raven Press: New York, pp. 821-839 (1992).
Folkman, “The angiogenic activity of FGF and its possible clinical applications,” inGrowth Factors: From Genes to Clinical Application(Sara, et al., eds.) Raven Press: New York, NY, pp. 201-216 (1990).
Frank, et al., “Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing,”J. Biol. Chem.270(21): 12607-12613 (1995).
Geerlings, et al., “Immune dysfunction in patients with diabetes mellitus (DM),”FEMS Immunol. Med. Microbiol.26(3-4): 259-265 (1999).
Gennaro, et al., “Age-dependent impairment of reendothelialization after arterial
Kelly Robert M
New York University
Pabst Patent Group LLP
LandOfFree
Method for treating diabetic ulcers with vectors encoding VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating diabetic ulcers with vectors encoding VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating diabetic ulcers with vectors encoding VEGF will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2732073